 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Animal Model:
|
Heterozygous Reeler Mouse
|
|
Preparation Type:
|
Genetic Preparations
|
|
DA-related behavior:
|
Enhanced mesolimbic dopamine
|
|
Gating:
|
Cross-modal PPI deficits, no unimodal PPI deficit
|
|
Cognitive behavior:
|
Decreased working memory; no decrease in prefrontal cortex
dependent task
|
|
Social behavior:
|
Impaired social interaction
|
|
Molecular/morphological signature:
|
Reduced GAD 67, increased DNA methylation; increased
truncated TrkB receptor, decreased BDNF/TrkB signaling in
frontal cortex
|
|
Citations:
|
Ballmaier M, Zoli M, Leo G, Agnati LF, Spano P. Preferential
alterations in the mesolimbic dopamine pathway of
heterozygous reeler mice: an emerging animal-based model of
schizophrenia. Eur J Neurosci . 2002 Apr 1 ; 15(7):1197-205.
Abstract
Costa E, Davis J, Pesold C, Tueting P, Guidotti A.
The heterozygote reeler mouse as a model for the development
of a new generation of antipsychotics. Curr Opin Pharmacol .
2002 Feb 1 ; 2(1):56-62.
Abstract
Podhorna J, Didriksen M. The heterozygous reeler
mouse: behavioural phenotype. Behav Brain Res . 2004 Aug 12
; 153(1):43-54. Abstract
|
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: